The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function

Behavioural Brain Research

Volumn 160, Issue 1, 2005, Pages 148-160

  Willis, Gregory L ^a  

^a Bronowski Clinic   (Australia)

Author keywords

Amantadine; Bromocriptine; Dopamine degeneration; l Dopa; Melatonin; PD; Pineal gland

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE; BROMOCRIPTINE; DOPAMINE; LEVODOPA; OXIDOPAMINE;

AGITATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DARKNESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EMOTIONALITY; ESCAPE BEHAVIOR; INJECTION; LIGHT; LIGHT DARK CYCLE; MALE; MEASUREMENT; MENTAL DISEASE; MENTAL FUNCTION; MOTOR PERFORMANCE; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PINEAL BODY; PINEALECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAGE; RAT; REFLEX; SCORING SYSTEM; STRIATONIGRAL DEGENERATION; SUBSTITUTION THERAPY; TASK PERFORMANCE;

EID: 17044426680     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2004.11.030     Document Type: Article

References (65)

1. A. Altar, D. Goldwag, R.L. Terry, and L.D. Lytle Synergistic induction of pineal gland n-acetyltransferase activity by amphetamine and l-Dopa Proc West Pharmacol Soc 24 1981 303 308
2. F. Anton-Tay Melaton: effects on brain function Adv Biochem Pharmacol 11 1974 315 324
3. F. Anton-Tay, J.L. Diaz, and C. Fernandez-Guardiola On the effect of melatonin upon the human brain. Its possible therapeutic implications Life Sci 10 Part 1 1971 841 850
4. S.H. Appel A unifying hypothesis for the cause of amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer disease Ann Neurol 10 1981 499 505
5. A.R. Artemenko, and Y.J. Lewin Light therapy of patients with Parkinson's disease Zh Nevropato Psikhiatr Im S S Korsakova 96 3 1996 63 66
6. T. Asami, H. Kuribara, and S. Todocoro Effects of repeated administration of Bromocriptine on ambulatory activity in mice, and changes in methylamphetamine sensitivity in Bromocriptine-experienced mice Yakubatsu Seinshin Kudo 1986 309 317
7. S.A. Balagura, R.H. Wilcox, and D.V. Cochina The effects of diencephalic lesions on food intake and motor control Physiol Behav 4 1969 629 633
8. A.K. Banerjee, P.G. Falkai, and M. Savidge Visual hallucinations in the elderly associated with the use of levodopa Postgrad Med J 65 1989 358 361
9. L.J. Bell, L.I. Iversen, and N.J. Uretsky Time course of the effects of 6-hydroxydopamine on catecholamine-containing neurones in rat hypothalamus and striatum Brit J Pharmacol 42 1971 88 89
10. C.J. Bojkowski, and J. Arendt Factors influencing urinary 6-sulphatoxymelatonin; a major melatonin metabolite in normal human subjects Clin Endocrinol 35 1990 435 444
11. R. Bordet, D. Devos, S. Brique, Y. Touitou, J.D. Guieu, and C. Libersa Study of circadian melatonin secretion pattern at different stages of Parkinson's disease Clin Neuropharmacol 26 2 2003 65 72
12. W.T. Burke, D.H. Park, H.D. Chung, G.L. Marshall, J.H. Haring, and T.H. Joh Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease Brain Res 537 1990 83 87
13. S. Burton, S. Daya, and B. Potgeiter Melatonin modulates apomorphine-induced rotational behaviour Experientia 47 1991 466 469
14. D.B. Calne, and M. Sandler L-Dopa in Parkinsonism Nature 26 1970 21 24
15. D.P. Cardinalli, and F. Friere Melatonin effects on brain: interaction with microtubular protein, inhibition of fast axonal transport flow and induction of crystalloid formation in the hypothalamus Cell Endocrinol 2 1995 317 330
16. D.P. Cardinale, C.A. Nagle, F. Friere, and J.M. Rosner Effect of melatonin on neurotransmitter uptake and release by synaptosome-rich homogenates in rat hypothalamus Neuroendocrinology 18 1975 72 85
17. D.P. Cardoso, and T.S. Jankovic Dystonia and dyskinaesia Psychiatr Clin N Am 20 1997 821 838
18. H.J. Carlisle, and R.W. Reynolds Effects of amphetamine on food intake in rats with brain stem lesions Am J Physiol 201 1961 965 967
19. J.C. Commentz, P. Fischer, H. Stegner, P. Winkler, K. Helmke, and R.D. Willig Pineal calcification does not affect pineal production J Neural Transm 21 1986 481
20. Descartes, R. The passions of the Soule. London: Printed for A.C., 1650 [English Edition].
21. E. Fertl, E. Auff, A. Dopplebauer, and F. Waldhauser Circadian secretion pattern of melatonin in Parkinson's disease J Neural Transm 3 1991 41 47 (PD Section)
22. E. Fertl, E. Auff, A. Dopplebauer, and F. Waldhauser Circadian secretion pattern of melatonin in novo Parkinson's patient. Evidence for phase shifting properties of l-Dopa J Neural Transm 5 1993 227 234 (PD Section)
23. J.S. Fink, and G.P. Smith l-Dopa repairs deficits in locomotor and investigatory exploration produced by denervation of catecholamine terminal fields in the forebrain of rats J Comp Physiol Psych 93 1979 66 73
24. A. Fredriksson, A. Plaznik, E. Sandstrom, G. Jonsson, and T. Archer MPTP induced hypoactivity in mice: reversal by l-Dopa Pharmacol Toxicol 67 1990 295 301
25. M. Ghaemi, J. Rudolf, R. Hilker, K. Herholz, and W.D. Heiss Increased pineal f-Dopa uptake is related to severity of Parkinson's disease - A PET study J Pineal Res 30 4 2001 213 219
26. D.C. Gajdusek Hypothesis: interference with axonal transport of neurofilaments as a common pathogenic mechanism in certain diseases of the central nervous system New Eng J Med 312 11 1985 714 719
27. J.E. Goldman, and S.-H. Yen Cytoskelatal protean abnormalities in neurodegenerative diseases Ann Neurol 19 1986 209 223
28. A.C. Greiner, and G.A. Nicolson Schizophrenia-melanosis: cause or side effect? Lancet 1965 1165 1167
29. B. Guardiola-Lemaitre Toxicology of melatonin J Biol Rhyth 12 6 1997 697 706
30. A. Hasegawa, K. Ahtsubo, and W. Mori Pineal gland in old age: quantitative and qualitative morphological study of 168 human autopsies Brain Res 409 1987 343 349
31. G. Heinze-Martin Melatonin in psychiatry Gac. Med. Mex. 133 1 1997 49 51
32. K. Helmke, and P. Winkler Incidence of pineal calcification in the first 18 years of life ROFO Forschr Geb Rontgenstr Nuklearmed 144 2 1986 21 226
33. K.A. Jellinger Post mortem studies in Parkinson's disease - it is possible to detect brain areas for specific symptoms J Neural Transm 56 Suppl. 1999 1 29
34. J.F. Marshall, B.H. Turner, and P. Teitelbaum Sensory neglect produced by lateral hypothalamic damage Science 174 1971 523 525
35. A.J. Lewis, N.A. Kerenyi, and G. Feurer Neuropharmacology of pineal secretions Drug Metab Drug Interact 8 3/4 1990 247 312
36. D.H. Matsui, and G.M. Machado-Santelli Alterations in f-actin distribution in cells treated with melatonin J Pin Res 23 1997 169 175
37. J.C. Mayo, R.M. Sainz, H. Uria, I. Antolin, M.M. Esteban, and C. Rodriguez Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease J Pin Res 24 3 1998 179 192
38. R. Medina-Navarro, G. Duran-Reyes, and J.J. Hicks Pro-oxidating properties of melatonin in the in vitro interaction with the singlet oxygen Endocrinol Res 25 3/4 1999 263 280
39. J. Melendez, V. Malonado, and A. Ortega Effect of melatonin on β-tubulin and MAP-2 expression in N1E-115 cells Neurochem Res 21 6 1996 653 658
40. F.S. Messiha Mouse strain dependent effect of Amantadine on motility and brain biogenic amines Arch Int Pharmacodyn Ther 302 1989 74 85
41. R. Morsch, Simon, and P.D. Coleman Neurones may live for decades with neurofibrillary tangles J Neuropathol Exp Neurol 58 2 1999 188 197
42. C.W. Olanow, and R.A. Hauser The treatment of early Parkinson's disease S. Fahn The assessment of Parkinson's disease 1990 Parthenon Publishing UK 77 88
43. C. Pacchierptti, S. Iapichino, L. Bossini, F. Pieraccini, and P. Castrogiovanni Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry Front Neuroendocrin 22 1 2001 18 32
44. P.S. Papavasiliou, G.C. Cotzias, S.E. Düby, A.J. Steck, M. Bell, and W.H. Lawrence Melatonin and Parkinsonism JAMA 221 1 1972 88 89
45. L.L. Pelligrino, A.J. Pelligrino, and A.J. Cushman A stereotaxic atlas of the rat brain 1979 Plenum Press New York
46. D.L. Price, J.C. Cork, R.G. Struble, C.A. Kit, L.C. Walker, and R.E. Powers Dysfunction and death of neurones in human degenerative neurological diseases and in animal models Ciba Found Symp 126 1987 30 48
47. R.J. Reiter Oxidative damage in the central nervous system: protection by melatonin Prog Neurobiol 56 3 1998 359 384
48. R.J. Reiter, D.X. Tan, J. Cabrera, D. D'Arpa, R.N. Sainz, J.C. Mayo, and S. Ramos The oxidant/antioxidant network: role of melatonin Biol Signal Recept 8 1/2 1999 56 63
49. K.M. Shaw Hypothalamo-pituitary-adrenal function in Parkinsonian patients and patients treated with melatonin Curr Med Res Op 4 10 1977 743 746
50. K.M. Shaw, G.M. Stern, and M. Sandler Melatonin and Parkinsonism Lancet 1 1973 271
51. K.M. Shaw, G.M. Stern, and M. Sandler Melatonin and metatyrosine in the treatment of Parkinsonism Adv Neurol 3 1975 115
52. D.C. Skinner, and B. Malpaux High melatonin concentrations in third ventricular cerebrospinal fluid and not due to galen vein blood recirculating through the choroid plexus Endocrinology 140 4 1999 4399 4405
53. Y.P. Tang, Y.L. Ma, C.C. Chao, K.Y. Chen, and H.Y. Lee Enhanced glial cell line revives neurotrophic factor MRNA expression upon [-]-deprenyl and melatonin treatments J Neurosci Res 53 1998 593 604
54. G.M. Vaughan, R.D. Bell, and R.M. Boyar Melatonin rhythm in Parkinsonism treated with a dopamine agonist C.D. Matthews R.F. Seamark Pineal Function 1981 Elsevier/North Holland Biomedical Press Amsterdam 19 25
55. L. Wetterberg Melatonin in humans. Physiological and clinical studies J Neural Trans 13 Suppl. 1978 289 310
56. P.F. Vonvoigtlander Axonal transport: reciprocal effect of neuroleptics and d-amphetamine. Brain Res 72 1974 370 374
57. G.L. Willis, and S.M. Armstrong Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease Brain Res Rev 27 1998 177 242
58. G.L. Willis, and S.M. Armstrong A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease Physiol Behav 66 5 1999 785 795
59. G.L. Willis, and G.A. Kennedy The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease Rev Neurosci 15 2004 75 87
60. G.L. Willis, and C.A. McLennan Therapeutic effects of bright light therapy in Parkinson's disease: a series of case reports Proceedings of the Melatonin and Biol Rhythms on Symposium of Sat Meet XXXIV Cong Physiol Sci Christchurch, New Zealand 2001 015
61. G.L. Willis, and A.D. Robertson Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor Pharmac Biochem Behav 73 3 2004 413 429
62. G.L. Willis, G. Singer, and B.K. Evans Intracranial injections of 6-OHDA: comparison of catecholamine depleting effects of different volumes and concentrations Pharmacol Biochem Behav 76 1976 207 213
63. G.L. Willis, G.C. Smith, and P.C. Kinchington Peripheral DA receptor blockade facilitates behavioural recovery from nigrostriatal damage Brain Res Bull 11 1983 15 19
64. G.L. Willis, G.C. Smith, and B.P. McGrath Deficits in locomotor behaviour and motor performance after central 6-hydroxydopamine or peripheral l-Dopa Brain Res 266 1983 279 286
65. N. Zisapel Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting Cell Mol Neurobiol 21 6 2001 605 616